Sign In
Last checked at 
6 May 2025 09:30
6 May 2025
RUA Life Sciences Plc
("RUA Life Sciences", the "Company" or the "Group")
Director/PDMR Shareholding
RUA Life Sciences (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon™), announces that it has been notified that Lachlan Smith, Chief Financial Officer of the Company, on 2 May 2025, purchased 20,228 ordinary shares in the Company at 11.86 pence per ordinary share.
Following this purchase, Lachlan Smith is interested in 130,508 ordinary shares in the Company, representing approximately 0.21 per cent. of the Company's issued ordinary share capital.
The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Lachlan Smith | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Financial Officer | ||||
b) | Initial notification /Amendment | Initial | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | RUA Life Sciences plc | ||||
b) | LEI | 213800BMVB22PVOJ9Z28 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
Transaction | ||||||
a)
| Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 5 pence each
ISIN: GB0033360586 | ||||
b) | Nature of the transaction | Purchase of Ordinary Shares | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information - Aggregated volume - Price | N/A (Single transaction) | ||||
e) | Date of the transaction | 2 May 2025 | ||||
f) | Place of the transaction | London Stock Exchange, AIM | ||||
- Ends -
For further information contact:
RUA Life Sciences Bill Brown, CEO Lachlan Smith, CFO |
Tel: +44 (0)1294 317073 Tel: +44 (0)1294 317073
|
Cavendish Capital Markets Limited (Nominated Adviser and Broker) Giles Balleny/Dan Hodkinson (Corporate Finance) Charlie Combe (Broking) Michael Johnson (Sales) | Tel: +44 (0)20 7220 0500
|
About RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.
Our vision is to improve the lives of millions of patients by enabling medical devices with Elast-EonTM, the world's leading long-term implantable polyurethane. Whether it is licensing Elast-EonTM, manufacturing a device or component, or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.
Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 8 million implants and 15 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.
The Group's four business units are:
RUA Contract Manufacture: | End-to-end contract developer and manufacturer of medical devices and implantable fabric specialist.
|
RUA Biomaterials: | Licensor of Elast-EonTM polymers to the medical device industry.
|
RUA Vascular: | Commercialisation of open surgical vascular grafts and patches
|
RUA Structural Heart: | Development of polymeric leaflet systems for heart valves. |
Follow the stocks
